Stocksigma LogoStocksigma Logo

US FDA Issues Form 483 With Three Observations for Aarti Drugs Subsidiary

The US FDA inspected the Baddi, Himachal Pradesh formulations manufacturing facility of Aarti Drugs Limited鈥檚 wholly-owned subsidiary, Pinnacle Life

US FDA Issues Form 483 With Three Observations for Aarti Drugs Subsidiary

Aarti Drugs Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 10:33 pm

US FDA Issues Form 483 With Three Observations for Aarti Drugs Subsidiary The US FDA inspected the Baddi, Himachal Pradesh formulations manufacturing facility of Aarti Drugs Limited鈥檚 wholly-owned subsidiary, Pinnacle Life Science Private Limited, from 2nd Nov'26 to 6th Nov'26. Upon concluding the inspection, the agency issued Form 483 containing three inspectional observations, none of which pertain to data integrity. Aarti Drugs confirmed that it will work closely with the regulator to resolve all points and stated that the observations have no impact on the company's financial, operational, or other business activities.

Original exchange filing (PDF)

More announcements from Aarti Drugs Ltd

All Aarti Drugs Ltd announcements